MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2019 International Congress

    Efficacy, Safety, and Tolerability of Supratherapeutic Doses of Apomorphine Sublingual Film for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease

    C. Olanow, F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, R. Kleiman, D. Blum, B. Navia (New York, NY, USA)

    Objective: To evaluate efficacy, safety, and tolerability of supratherapeutic doses of apomorphine sublingual film (APL-130277; APL) in patients with Parkinson’s disease (PD) and “OFF” episodes.…
  • 2019 International Congress

    Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study

    R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl, K. Chaudhuri, T. Henriksen, T. van Laar, D. Lockhart, A. Lees (London, United Kingdom)

    Objective: To evaluate the long-term safety and efficacy of apomorphine infusion (APO) in PD patients with motor fluctuations despite optimised oral therapy. Background: The randomised,…
  • 2019 International Congress

    Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis

    W. Ondo, A. Ellenbogen, S. Isaacson, A. Espay, C. Singer, P. Bhargava, M. Worden, D. Blum, B. Navia (Houston, TX, USA)

    Objective: To examine safety and tolerability of apomorphine sublingual film (APL-130277; APL) during maintenance treatment using pooled data from 4 clinical studies in patients with…
  • 2019 International Congress

    Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions

    C. Marse, J. Benoit, F. Rocher, C. Giordana (Nice, France)

    Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…
  • 2019 International Congress

    A Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson’s Disease Complicated By “OFF” Episodes

    F. Stocchi, K. Wilks, E. Peckham, M. de Pandis, K. Sciarappa, F. Agbo, R. Kleiman, D. Blum, B. Navia (Rome, Italy)

    Objective: To assess the effect of apomorphine sublingual film (APL130277; APL) on the QT interval in patients with Parkinson’s disease (PD) and “OFF” episodes participating…
  • 2019 International Congress

    Management of Akinesia in Parkinson’s Disease with Apomorphine Subcutaneous Injection

    F. Rakhimov, B. Sultanov (Tashkent, Uzbekistan)

    Objective: To assess the effect of apomorphine on time-to-ON in PD patients with morning akinesia. Background: In patients with motor fluctuations complicating Parkinson's disease (PD), delays in time-to-ON…
  • 2019 International Congress

    Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

    R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)

    Objective: To establish a registry of PD patients in Thailand treated with subcutaneous apomorphine (APO) injection or infusion to allow prospective data collection from the…
  • 2019 International Congress

    The Effects of Apomorphine infusion on Head ptosis, a case report

    O. Skogar (Stockholm, Sweden)

    Objective: Sustained Effects of Apomorphine infusion on Head Ptosis, a case report Background: IntroductionHead ptosis (Hp) results from weakness of the neck extensor, or increased…
  • 2019 International Congress

    Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017

    L. Tönges, D. Bartig, C. Krogias, D. Richter (Bochum, Germany)

    Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…
  • 2019 International Congress

    Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine

    RWK. Borgemeester, GFH. Diercks, T. van Laar (Groningen, Netherlands)

    Objective: To evaluate the efficacy of 4 treatment modalities on apomorphine-induced subcutaneous nodules as compared to no treatment. Background: Subcutaneous nodules are the most common adverse events…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley